Results 21 to 30 of about 21,815 (182)

Diffuse hyperpigmented lichenoid drug eruption secondary to Enzalutamide

open access: yesCurrent Problems in Cancer: Case Reports, 2022
Enzalutamide is a potent second-generation androgen receptor (AR) antagonist used to treat metastatic castration resistant prostate carcinoma (mCPRC) and metastatic hormone sensitive prostate carcinoma (mHSPC).
Sabrina Khan   +4 more
doaj   +1 more source

Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer

open access: yesMolecular Oncology, 2020
Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD).
Yukiyoshi Hirayama   +4 more
doaj   +1 more source

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.

open access: yesPLoS ONE, 2020
Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs.
Holger H H Erb   +12 more
doaj   +1 more source

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

open access: yesFrontiers in Oncology, 2021
ObjectiveThe androgen receptor-targeting drugs abiraterone acetate and enzalutamide have shown positive results as treatments for metastatic castration-resistant prostate cancer (mCRPC).
ZhenHeng Wei   +4 more
doaj   +1 more source

Targeting DNMTs to overcome enzalutamide resistance in prostate cancer

open access: yes, 2022
Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is a FDA-approved drug for treatment of patients with late-stage prostate cancer and is currently under ...
Liu, Jinpeng   +6 more
core   +1 more source

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide

open access: yesFrontiers in Pharmacology, 2022
Background: Enzalutamide is useful for the treatment of castration-resistant prostate cancer (CRPC). Despite its usefulness, adverse events (AEs) sometimes force patients to discontinue treatment. To maximize patient care, we developed an ambulatory care
Masaki Hirabatake   +9 more
doaj   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment

open access: yesJournal for ImmunoTherapy of Cancer, 2023
Background Emerging data suggest that patients with enzalutamide-treated prostate cancer with increased programmed death-ligand 1 (PD-L1) expression may benefit from anti-PD-L1 treatment. Unfortunately, the Phase III IMbassador250 clinical trial revealed
Bo Chen   +9 more
doaj   +1 more source

The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday

open access: yesCase Reports in Oncology, 2019
While the overall survival of patients with castration-resistant prostate cancer (CRPC) has been prolonged by enzalutamide, a considerable number of patients suffer from enzalutamide-induced nausea and fatigue.
Takashi Kawahara   +3 more
doaj   +1 more source

Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer

open access: yesTherapeutic Advances in Urology, 2013
The treatment of metastatic castrate-resistant prostate cancer (mCRPC) has evolved rapidly with the recent approval of a number of treatments and agents, including docetaxel, sipuleucel T, abiraterone, cabazitaxel, and enzalutamide.
Fred Saad
doaj   +1 more source

Home - About - Disclaimer - Privacy